The metabolic syndrome in cancer survivors

Esther C de Haas; Sjoukje F Oosting; Joop D Lefrandt; Bruce Hr Wolffenbuttel; Dirk Th Sleijfer; Jourik A Gietema

doi:10.1016/S1470-2045(09)70287-6

The metabolic syndrome in cancer survivors

Lancet Oncol. 2010 Feb;11(2):193-203. doi: 10.1016/S1470-2045(09)70287-6.

Authors

Esther C de Haas¹, Sjoukje F Oosting, Joop D Lefrandt, Bruce Hr Wolffenbuttel, Dirk Th Sleijfer, Jourik A Gietema

Affiliation

¹ Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.

PMID: 20152771
DOI: 10.1016/S1470-2045(09)70287-6

Abstract

The metabolic syndrome, as a cluster of cardiovascular risk factors, may represent an important connection between cancer treatment and its common late effect of cardiovascular disease. Insight into the aetiology of the metabolic syndrome after cancer treatment might help to identify and treat cancer survivors with increased cardiovascular risk. In this review, we summarise current knowledge on the prevalence and pathophysiology of the metabolic syndrome in cancer survivors, and discuss current intervention strategies with an emphasis on new developments.

Publication types

Review

MeSH terms

Humans
Metabolic Syndrome / complications
Metabolic Syndrome / epidemiology
Metabolic Syndrome / etiology
Metabolic Syndrome / physiopathology*
Metabolic Syndrome / therapy
Neoplasms / complications*
Neoplasms / therapy
Prevalence
Survivors